Use of Nicorandil in Cardiovascular Disease and Its Optimization
暂无分享,去创建一个
[1] J. Tijssen,et al. Efficacy of nicorandil versus propranolol in mild stable angina pectoris of effort: a long-term, double-blind, randomized study. , 1992, Journal of cardiovascular pharmacology.
[2] J. Sasaki,et al. A multicenter comparison of nicorandil and diltiazem on serum lipid, apolipoprotein, and lipoprotein levels in patients with ischemic heart disease , 1992, Cardiovascular Drugs and Therapy.
[3] A. Fitton,et al. Nicorandil. A review of its pharmacology and therapeutic efficacy in angina pectoris. , 1992, Drugs.
[4] N. Taira,et al. Nicorandil as a hybrid between nitrates and potassium channel activators. , 1989, The American journal of cardiology.
[5] R. Mann,et al. Safety profile of nicorandil—prescription‐event monitoring (PEM) study , 1999, Pharmacoepidemiology and drug safety.
[6] E. Roland. Safety profile of an anti-anginal agent with potassium channel opening activity: an overview. , 1993, European heart journal.
[7] A. Camm,et al. Exercise capacity after single and twice-daily doses of nicorandil in chronic stable angina pectoris. , 1989, The American journal of cardiology.
[8] M. Kinoshita,et al. Absence of hemodynamic tolerance to nicorandil in patients with severe congestive heart failure. , 1994, American heart journal.
[9] K. Shirato,et al. Vasodilatory effect of nicorandil on coronary arterial microvessels: its dependency on vessel size and the involvement of the ATP-sensitive potassium channels. , 1995, Journal of cardiovascular pharmacology.
[10] R M Rapoport,et al. Endothelium-dependent and nitrovasodilator-induced relaxation of vascular smooth muscle: role of cyclic GMP. , 1983, Journal of cyclic nucleotide and protein phosphorylation research.
[11] P. Quandalle,et al. Potassium channel activators in vasospastic angina. , 1993, European heart journal.
[12] J. Downey,et al. Nicorandil opens mitochondrial KATP channels not only directly but also through a NO-PKG-dependent pathway , 2006, Basic Research in Cardiology.
[14] D. Fukai,et al. Comparison of hemodynamic effects and plasma cyclic guanosine monophosphate of nicorandil and nitroglycerin in patients with congestive heart failure. , 1995, The American journal of cardiology.
[15] M. Egred. Nicorandil-associated ulcerations , 2007, European Journal of Gastroenterology and Hepathology.
[16] N. Chang,et al. Effect of ATP-sensitive potassium channel agonists on sympathetic hyperinnervation in postinfarcted rat hearts. , 2009, American journal of physiology. Heart and circulatory physiology.
[17] R. Luke. Chronic renal failure--a vasculopathic state. , 1998, The New England journal of medicine.
[18] Katherine C. Wu,et al. Prognostic significance of microvascular obstruction by magnetic resonance imaging in patients with acute myocardial infarction. , 1998, Circulation.
[19] 充男 三田,et al. 安定狭心症に対するニコランジルの短期的有効性・安全性に関するシステマティック・レビュー:β遮断薬・持続性亜硝酸薬・Ca拮抗薬との比較 , 2010 .
[20] R. Bolli. The Late Phase of Preconditioning , 2000, Circulation research.
[21] J. Camm,et al. Guidelines on the management of stable angina pectoris: executive summary: The Task Force on the Management of Stable Angina Pectoris of the European Society of Cardiology. , 2006, European heart journal.
[22] I. West,et al. The Mechanism by Which the Mitochondrial ATP-sensitive K+ Channel Opening and H2O2 Inhibit the Mitochondrial Permeability Transition* , 2006, Journal of Biological Chemistry.
[23] B. Gersh. Human atrial natriuretic peptide and nicorandil as adjuncts to reperfusion treatment for acute myocardial infarction (J-WIND): two randomised trials , 2008 .
[24] A. Barbaud,et al. Major aphthous stomatitis induced by nicorandil , 2000 .
[25] J. Camm,et al. [Guidelines on the management of stable angina pectoris: executive summary]. , 2006, Giornale italiano di cardiologia.
[26] M. Zeier,et al. Increased Infarct Size in Uremic Rats: Reduced Ischemia Tolerance? Materials and Methods , 2022 .
[27] A. Halestrap. What is the mitochondrial permeability transition pore? , 2009, Journal of molecular and cellular cardiology.
[28] P. Blin,et al. A double-blind comparison of the long-term efficacy of a potassium channel opener and a calcium antagonist in stable angina pectoris. , 1993, European heart journal.
[29] S. Holzmann. Cyclic GMP as Possible Mediator of Coronary Arterial Relaxation by Nicorandil (SG‐75) , 1983, Journal of cardiovascular pharmacology.
[30] Y. Hiraoka,et al. Continuous administration of nicorandil decreases QT dispersion during the chronic phase of acute myocardial infarction. , 2006, International heart journal.
[31] H. Yagi,et al. Nicorandil Protects Against Lethal Ischemic Ventricular Arrhythmias and Up-regulates Endothelial Nitric Oxide Synthase Expression and Sulfonylurea Receptor 2 mRNA in Conscious Rats with Acute Myocardial Infarction , 2004, Cardiovascular Drugs and Therapy.
[32] P. Bernardi,et al. Opening of the Mitochondrial Permeability Transition Pore Causes Depletion of Mitochondrial and Cytosolic NAD+and Is a Causative Event in the Death of Myocytes in Postischemic Reperfusion of the Heart* , 2001, The Journal of Biological Chemistry.
[33] N. Tamura,et al. Nicorandil Attenuates FeCl3-Induced Thrombus Formation Through the Inhibition of Reactive Oxygen Species Production , 2009 .
[34] F. Boccara. Coronary intervention for persistent occlusion after myocardial infarction. , 2007 .
[35] E. Cantor,et al. Comparison of nicorandil-induced relaxation, elevations of cyclic guanosine monophosphate and stimulation of guanylate cyclase with organic nitrate esters. , 1991, The Journal of pharmacology and experimental therapeutics.
[36] W. Laskey,et al. Adaptation to ischemia during percutaneous transluminal coronary angioplasty. Clinical, hemodynamic, and metabolic features. , 1990, Circulation.
[37] Y. Ladilov,et al. Preconditioning with diazoxide prevents reoxygenation-induced rigor-type hypercontracture. , 2010, Journal of molecular and cellular cardiology.
[38] E. Antman,et al. Prospective temporal analysis of the onset of preinfarction angina versus outcome: an ancillary study in TIMI-9B. , 1998, Circulation.
[39] H. Kishida,et al. Effect of a new coronary vasodilator, nicorandil, on variant angina pectoris , 1987, Clinical pharmacology and therapeutics.
[40] G. Pöch,et al. Pharmacological interaction experiments differentiate between glibenclamide-sensitive K+ channels and cyclic GMP as components of vasodilation by nicorandil. , 1992, European journal of pharmacology.
[41] K. Fox,et al. Cardioprotection by opening of the KATPchannel in unstable anginaIs this a clinical manifestation of myocardial preconditioning? Results of a randomized study with nicorandil , 1999 .
[42] R. Foley,et al. Outcome and risk factors of ischemic heart disease in chronic uremia. , 1996, Kidney international.
[43] F. Hofmann,et al. Cyclic GMP-dependent protein kinase stimulates the plasmalemmal Ca2+ pump of smooth muscle via phosphorylation of phosphatidylinositol. , 1988, The Biochemical journal.
[44] T. Yanagisawa,et al. Effect of 2-nicotinamidethyl nitrate (SG-75) on membrane potentials of canine Purkinje fibers. , 1981, Japanese journal of pharmacology.
[45] M. Isobe,et al. Opening of KATP channel attenuates the increase in QT dispersion produced by the first balloon inflation during coronary angioplasty , 2002 .
[46] M. Shigekawa,et al. Maxi K+ channels are stimulated by cyclic guanosine monophosphate-dependent protein kinase in canine coronary artery smooth muscle cells , 1993, Pflügers Archiv.
[47] M. Sekiguchi,et al. Coronary microvascular response to intracoronary administration of nicorandil. , 1995, The American journal of cardiology.
[48] M. Sekiya,et al. Effects of the Long-Term Administration of Nicorandil on Vascular Endothelial Function and the Progression of Arteriosclerosis , 2005, Journal of cardiovascular pharmacology.
[49] T. Katagiri,et al. Acute effects of intravenous nicorandil on hemodynamics in patients hospitalized with acute decompensated heart failure. , 2010, Journal of cardiology.
[50] M. Kurabayashi,et al. Comparative effects of nicorandil with isosorbide mononitrate on cardiac sympathetic nerve activity and left ventricular function in patients with ischemic cardiomyopathy. , 2005, American heart journal.
[51] S. Duty,et al. The potassium channel openers: a new class of vasorelaxants. , 1990, Blood vessels.
[52] O. Divitiis,et al. A double-blind comparison of nicorandil and metoprolol in stable effort angina pectoris , 1993, Cardiovascular Drugs and Therapy.
[53] E. Raftery,et al. Comparison of nicorandil and atenolol in stable angina pectoris. , 1990, The American journal of cardiology.
[54] M. Kinoshita,et al. Mechanism of the vasodilatory action of nicorandil on coronary circulation in dogs , 1994, Cardiovascular Drugs and Therapy.
[55] J. Downey,et al. Oxygen radicals released during ischemic preconditioning contribute to cardioprotection in the rabbit myocardium. , 1997, Journal of molecular and cellular cardiology.
[56] H. Yagi,et al. Effects of nicorandil on cardiovascular events in patients with coronary artery disease in the Japanese Coronary Artery Disease (JCAD) study. , 2010, Circulation journal : official journal of the Japanese Circulation Society.
[57] Y. Taniyama,et al. Intravenous nicorandil can preserve microvascular integrity and myocardial viability in patients with reperfused anterior wall myocardial infarction. , 1999, Journal of the American College of Cardiology.
[58] Maria Mori Brooks,et al. A randomized trial of therapies for type 2 diabetes and coronary artery disease. , 2009, The New England journal of medicine.
[59] A. Terzic,et al. Effective Pharmacotherapy Against Oxidative Injury: Alternative Utility of an ATP-Sensitive Potassium Channel Opener , 2007, Journal of cardiovascular pharmacology.
[60] David A Harris,et al. Biochemical dysfunction in heart mitochondria exposed to ischaemia and reperfusion. , 2005, The Biochemical journal.
[62] W. Hillis,et al. Effect of nicorandil on coronary events in patients with stable angina: the Impact Of Nicorandil in Angina (IONA) randomised trial , 2002, The Lancet.
[63] G. Pöch,et al. Molecular Mechanism of Action of Nicorandil , 1992, Journal of cardiovascular pharmacology.
[64] Hakuo Takahashi,et al. Oral nicorandil to reduce cardiac death after coronary revascularization in hemodialysis patients: a randomized trial. , 2009, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[65] A. Collins,et al. Poor long-term survival after acute myocardial infarction among patients on long-term dialysis. , 1998, The New England journal of medicine.
[66] S. Pocock,et al. Seven-year outcome in the RITA-2 trial: coronary angioplasty versus medical therapy. , 2003, Journal of the American College of Cardiology.
[67] H. Yagi,et al. Nicorandil but not ISDN Upregulates Endothelial Nitric Oxide Synthase Expression, Preventing Left Ventricular Remodeling and Degradation of Cardiac Function in Dahl Salt-sensitive Hypertensive Rats With Congestive Heart Failure , 2006, Journal of cardiovascular pharmacology.
[68] T. Murohara,et al. Impact of a Single Intravenous Administration of Nicorandil Before Reperfusion in Patients With ST-Segment–Elevation Myocardial Infarction , 2005, Circulation.
[69] L. Toquero,et al. Anal ulceration associated with Nicorandil: case series and review of the literature , 2006, Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland.
[70] C. Scully,et al. Nicorandil-induced severe oral ulceration: a newly recognized drug reaction. , 1999, Oral surgery, oral medicine, oral pathology, oral radiology, and endodontics.
[71] K. Fox,et al. Cardioprotection by opening of the K(ATP) channel in unstable angina. Is this a clinical manifestation of myocardial preconditioning? Results of a randomized study with nicorandil. CESAR 2 investigation. Clinical European studies in angina and revascularization. , 1999, European heart journal.
[72] K. Kato. Haemodynamic and clinical effects of an intravenous potassium channel opener--a review. , 1993, European heart journal.
[73] M. Kurabayashi,et al. Long-Term Nicorandil Therapy Improves Cardiac Sympathetic Nerve Activity After Reperfusion Therapy in Patients with First Acute Myocardial Infarction , 2007, Journal of Nuclear Medicine.
[74] L. Kevin,et al. Ischemic preconditioning alters real-time measure of O2 radicals in intact hearts with ischemia and reperfusion. , 2003, American journal of physiology. Heart and circulatory physiology.
[75] S. Witchitz,et al. Nicorandil safety in the long-term treatment of coronary heart disease , 1995, Cardiovascular Drugs and Therapy.
[76] P. Joly,et al. Association of major aphthous ulcers and nicorandil , 1998, The Lancet.
[77] K. Wellington,et al. Nicorandil , 2012, Drugs.
[78] D. Escande,et al. K+ channel openers and 'natural' cardioprotection. , 1992, Trends in pharmacological sciences.
[79] M. Hori,et al. Opening of the adenosine triphosphate-sensitive potassium channel attenuates cardiac remodeling induced by long-term inhibition of nitric oxide synthesis: role of 70-kDa S6 kinase and extracellular signal-regulated kinase. , 2002, Journal of the American College of Cardiology.
[80] D. Hausenloy. Signalling pathways in ischaemic postconditioning , 2009, Thrombosis and Haemostasis.
[81] M. Ishihara,et al. Implications of prodromal angina pectoris in anterior wall acute myocardial infarction: acute angiographic findings and long-term prognosis. , 1997, Journal of the American College of Cardiology.
[82] Hakuo Takahashi,et al. Clinical Potential of Nicorandil to Inhibit Major Cardiac Events in Hemodialysis Patients with Suspected Myocardial Ischemia , 2009, Nephron Clinical Practice.
[83] R. Jennings,et al. Preconditioning with ischemia: a delay of lethal cell injury in ischemic myocardium. , 1986, Circulation.
[84] A. Halestrap. Calcium, mitochondria and reperfusion injury: a pore way to die. , 2006, Biochemical Society transactions.
[85] S. Hishinuma,et al. [Systematic review on the short-term efficacy and safety of nicorandil for stable angina pectoris in comparison with those of β-blockers, nitrates and calcium antagonists]. , 2010, Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan.
[86] M. Loudon,et al. Nicorandil associated anal ulceration , 2004, Age and ageing.
[87] C Antzelevitch,et al. Cellular basis for QT dispersion. , 1998, Journal of electrocardiology.
[88] Takashi Sugamori,et al. Effects of Long-term Nicorandil Administration on Endothelial Function, Inflammation, and Oxidative Stress in Patients Without Coronary Artery Disease , 2008, Journal of cardiovascular pharmacology.
[89] G. Pöch,et al. Dual Mechanism of the Relaxing Effect of Nicorandil by Stimulation of Cyclic GMP Formation and by Hyperpolarization , 1991, Journal of cardiovascular pharmacology.
[90] H. Yagi,et al. [Suppressive effect of nicorandil in ventricular arrhythmias after reperfusion therapy in patients with acute myocardial infarction]. , 2007, Journal of cardiology.
[91] C. Bauters,et al. Prevention of Coronary Spasm by Nicorandil: Comparison with Nifedipine , 1992, Journal of cardiovascular pharmacology.
[92] T. Ohe,et al. Intravenous administration of nicorandil immediately before percutaneous coronary intervention can prevent slow coronary flow phenomenon. , 2008, European heart journal.
[93] Ernesto Carafoli,et al. Calcium pump of the plasma membrane , 1991 .
[94] M. Kojima,et al. Nicorandil shortens action potential duration and antagonises the reduction of Vmax by lidocaine but not by disopyramide in guinea-pig papillary muscles , 1988, Naunyn-Schmiedeberg's Archives of Pharmacology.
[95] T. Yamamoto,et al. Rho‐associated kinase, a novel serine/threonine kinase, as a putative target for small GTP binding protein Rho. , 1996, The EMBO journal.
[96] S. Silberberg,et al. ATP inhibits smooth muscle Ca2+-activated K+ channels , 1990, Proceedings of the Royal Society of London. Series B: Biological Sciences.
[97] Zhan-quan Li,et al. Double-blind, multicenter, active-controlled, randomized clinical trial to assess the safety and efficacy of orally administered nicorandil in patients with stable angina pectoris in China. , 2007, Circulation journal : official journal of the Japanese Circulation Society.
[98] I. R. Manousos,et al. Clinical trials update: The Heart Protection Study, IONA, CARISA, ENRICHD, ACUTE, ALIVE, MADIT II and REMATCH , 2002, European journal of heart failure.
[99] N. Hagiwara,et al. Acute Efficacy and Safety of Intravenous Administration of Nicorandil in Patients With Acute Heart Failure Syndromes: Usefulness of Noninvasive Echocardiographic Hemodynamic Evaluation , 2009, Journal of cardiovascular pharmacology.
[100] T. Kato,et al. Nicorandil, a potent cardioprotective agent, reduces QT dispersion during coronary angioplasty. , 2001, American heart journal.
[101] Y. Izumiya,et al. Long-term use of oral nicorandil stabilizes coronary plaque in patients with stable angina pectoris. , 2011, Atherosclerosis.
[102] D. Levine,et al. Clinical Trials Update , 2013 .
[103] A. Terzic,et al. Cellular remodeling in heart failure disrupts KATP channel‐dependent stress tolerance , 2003, The EMBO journal.
[104] I. Ford,et al. Effect of nicorandil on coronary events in patients with stable angina: the Impact Of Nicorandil in Angina (IONA) randomised trial , 2002 .
[105] D. Berman,et al. Optimal medical therapy with or without PCI for stable coronary disease. , 2007, The New England journal of medicine.
[106] W. Howard,et al. Optimal Medical Therapy with or without PCI for Stable Coronary Disease , 2008 .
[107] 松原 徹夫. Three minute,but not one minute,ischemia and nicorandil have a preconditioning effect in patients with coronary artery disease , 2000 .
[108] Current status of the background of patients with coronary artery disease in Japan. , 2006, Circulation journal : official journal of the Japanese Circulation Society.
[109] H M Piper,et al. A fresh look at reperfusion injury. , 1998, Cardiovascular research.
[110] R. Cannon,et al. Cardiovascular complications in renal failure. , 1991, Journal of the American Society of Nephrology : JASN.
[111] N. Tsujino,et al. Mechanisms of preventive effect of nicorandil on ischaemia-induced ventricular tachyarrhythmia in isolated arterially perfused canine left ventricular wedges. , 2008, Basic & clinical pharmacology & toxicology.
[112] Hiroshi Takahashi,et al. Efficacy of oral nicorandil in patients with end-stage renal disease: a retrospective chart review after coronary angioplasty in Japanese patients receiving hemodialysis. , 2007, Clinical therapeutics.
[113] G. Döring. Antianginal and Anti‐Ischemic Efficacy of Nicorandil in Comparison with Isosorbide‐5‐Mononitrate and Isosorbide Dinitrate: Results from Two Multicenter, Double‐Blind, Randomized Studies with Stable Coronary Heart Disease Patients , 1992, Journal of cardiovascular pharmacology.
[114] 2007 Chronic Angina Focused Update of the ACC/AHA 2002 Guidelines for the Management of Patients With Chronic Stable Angina , 2007 .
[115] M. Chiariello,et al. Oxygen radicals can induce preconditioning in rabbit hearts. , 1997, Circulation research.
[116] G. Ulvenstam,et al. Antianginal and Anti‐Ischemic Efficacy of Nicorandil Compared with Nifedipine in Patients with Angina Pectoris and Coronary Heart Disease: A Double‐Blind, Randomized, Multicenter Study , 1992, Journal of cardiovascular pharmacology.
[117] E. Marbán,et al. Nicorandil, a potent cardioprotective agent, acts by opening mitochondrial ATP-dependent potassium channels. , 2000, Journal of the American College of Cardiology.
[118] K. Dickstein,et al. Comparison of the degree of hemodynamic tolerance during intravenous infusion of nitroglycerin versus nicorandil in patients with congestive heart failure. , 1997, American heart journal.
[119] M. Shibuya,et al. Nicorandil treatment in patients with acute myocardial infarction: a meta-analysis. , 2009, Circulation journal : official journal of the Japanese Circulation Society.